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Increasing attention is focused on the nature and origins of
chronic inﬂammation in patients with morbid obesity and non-
alcoholic fatty liver disease (NAFLD). Smoldering inﬂammation
without an obvious precipitant is also recognized in a range of
related disorders that includes atherosclerosis, dementia, type 2
diabetes and even cancer [1,2]. Studies of this ‘autoinﬂammation’
have zeroed in on an intracellular multi-protein scaffold known
as the inﬂammasome, whose primary function is to activate an
inﬂammatory cascade as part of the innate immune response’s
cytosolic surveillance [3,4]. Activation of the inﬂammasome cul-
minates in the auto-catalytic cleavage of caspase-1 that facilitates
processing and secretion of the inﬂammatory cytokines interleu-
kin (IL)-1b and IL-18. In other words, increased IL-1b is among
the most important consequences of inﬂammasome activation.
While originally characterized in classic immune cells, it is now
clear that the inﬂammasome is also present in non-immune cells,
including hepatocytes and hepatic stellate cells, as well as hepatic
macrophages and dendritic cells. Inﬂammasomes are classiﬁed
by the speciﬁc type of pattern recognition receptors (PRRs)
within the inﬂammasome that have evolved to distinguish
among a range of stimuli (e.g., bacterial or viral proteins, or crys-
tals). Among these, for example, the Nod-like receptor (NLR) fam-
ily of innate immune cell sensors, speciﬁcally NLRP3 (also known
as NALP3 or cryopyrin), has been linked to obesity-induced
inﬂammation [1].
IL-1, which was ﬁrst described as an endogenous pyrogen in
the 1940’s, actually consists of two structurally similar but dis-
tinct proteins, IL-1a and IL-1b [5]. IL-1b is implicated in a range
of inﬂammatory diseases and thus efforts to antagonize the pro-
tein are an attractive therapeutic strategy. This prospect is under-
scored by a recent study by Kamari et al. published in the Journal
[6], and summarized in a lovely editorial [7], in which mice lack-
ing either IL-1a or IL-1b had markedly reduced steatohepatitis
and ﬁbrosis when fed an atherogenic diet. Interestingly, nature
has already generated its own IL-1b antagonist, the IL-1 receptor
antagonist (IL-1Ra). IL-1Ra was identiﬁed as the ﬁrst naturally
occurring cytokine receptor antagonist and was initially
described as an acute-phase protein. It competes for binding of
IL-1 to its cognate receptor, yet it does not elicit signaling. Of
the four IL-1Ra isoforms, one is secreted (sIL-1Ra), whereas the
other three remain in the cell unless they are liberated whenJournal of Hepatology 20
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Open access under CC BY-NC-ND license.the cell dies. Both knockout mice and children with IL-1Ra deﬁ-
ciency have marked autoinﬂammation, attesting to the physio-
logic importance of the molecule in preserving immune
homeostasis.
In this month’s issue of the Journal, the study by Pihlajamaki
and colleagues from Finland identiﬁes elevated sIL-R1a as an
independent marker of human NASH severity. They correlated
serum levels of sIL-R1a with liver histology in 119 morbidly
obese men undergoing bariatric surgery, and additionally corre-
lated serum levels of the molecule with ALT levels among 6447
men from a cross-sectional cohort. In those undergoing surgery,
a decrease in sIL-R1a correlated with improvement in lobular
inﬂammation. The investigators used this information to gener-
ate a reﬁned NAFLD liver inﬂammation score whose performance
exceeded existing scoring systems. The ﬁndings complement a
recent study from Austria, in which IL-Ra1 levels also dropped
after bariatric surgery, but the latter study additionally deter-
mined that the bulk of IL-R1a mRNA expression was in adipose,
not the liver [8]. The single-site Finnish study is somewhat lim-
ited by the inclusion only of men, the review of biopsies by a sin-
gle pathologist, and the lack of correlation of sIL-1Ra with
hepatocyte ballooning, the most characteristic histologic feature
of NASH. Still, it is novel and intriguing.
The much bigger – and completely obscure – issue is the
underlying pathophysiology of sIL-1Ra elevation in the context
of systemic autoinﬂammation and NASH. IL-1Ra is an anti-
inﬂammatory molecule, yet its elevation is a marker of inﬂamma-
tion in NASH and other inﬂammatory diseases. Is the elevation of
sIL-1Ra in obesity and NASH a counter-regulatory response that
is ineffective in attenuating the autoinﬂammatory cascade? In
severe autoinﬂammatory diseases a recombinant IL-1 receptor
antagonist, anakinra, is a highly effective therapy so that sIL-
1Ra should be attenuating inﬂammation in fatty liver disease as
well [9]. Also, are the signals driving hepatic inﬂammation and
their counter-regulators largely derived from adipose rather than
the liver? On the one hand, the earlier study by Kamari has impli-
cated the liver as the key source of IL-1a [6], whereas adipose
may provide the bulk of IL-1b. There is precedent for exactly a
scenario wherein a beneﬁcial protein circulates at high levels in
the face of ongoing disease in studies of leptin, the adipogenic
hormone that promotes weight loss and increased metabolic
activity. Obese patients are typically hyperleptinemic because
serum levels are directly correlated with adipose mass, yet these
patients are effectively leptin-resistant, much like type 2 diabet-
ics are relatively insulin-resistant with high circulating insulin12 vol. 56 j 511–512
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levels. Are obese patients similarly resistant to sIL-1Ra? If so,
what is the mechanism that confers this resistance?
It’s obvious that we are barely scratching the surface in under-
standing the role of IL-1 signaling and the inﬂammasome in
hepatic physiology and disease. Moreover, recent experimental
models highlight the importance of the inﬂammasome not only
in inﬂammation but also in tissue ﬁbrosis [10] and hepatic stel-
late cell activation [11]. Nonetheless, large clinical studies like
that of Pihlajamaki and colleagues help frame the key questions
to be answered experimentally using animal models and molec-
ular approaches. The search to clarify the inﬂammasome’s role in
liver disease is just beginning.Conﬂict of interest
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